[新型冠状病毒2型（SARS-CoV-2）疫苗接种的现状]
[Current state of vaccination against SARS-CoV-2].
作者信息
Iking-Konert Christof, Specker Christof, Krüger Klaus, Schulze-Koops Hendrik, Aries Peer
机构信息
III. Medizinische Klinik und Poliklinik Sektion Rheumatologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Deutschland.
Klinik für Rheumatologie und Klinische Immunologie, Evangelisches Krankenhaus Kliniken Essen-Mitte, Essen, Deutschland.
出版信息
Z Rheumatol. 2021 Mar;80(2):158-164. doi: 10.1007/s00393-021-00966-9. Epub 2021 Feb 2.
On 21 December 2020 the European Medicines Agency (EMA) approved the mRNA vaccine BNT162b2 (Comirnaty®, BioNTech, Mainz, Germany; Pfizer, New York City, NY, USA) as the first vaccine against SARS-CoV‑2 in the European Union and the second vaccine (Moderna®, Moderna, Cambridge, MA, USA) followed on 6 January 2021. Many more approvals will follow within a short period of time. With the availability of the vaccination many questions have arisen for patients as well as for physicians, which are addressed as up to date as possible in this hot topic article.
2020年12月21日，欧洲药品管理局（EMA）批准了mRNA疫苗BNT162b2（Comirnaty®，德国美因茨BioNTech公司；美国纽约市辉瑞公司）作为欧盟首款针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗，第二款疫苗（Moderna®，美国马萨诸塞州剑桥市Moderna公司）于2021年1月6日获批。在短时间内还会有更多疫苗获得批准。随着疫苗的可及性，患者和医生都出现了许多问题，在这篇热点文章中会尽可能及时地予以解答。
Zotero 插件